Forum: ProQR Therapeutics » ProQR Therapeutics 2019 | Beursduivel.be

ProQR Therapeutics 2019

1.035 Posts, Pagina: « 1 2 3 4 5 6 ... 47 48 49 50 51 52 | Laatste
Aantal posts per pagina:  20 50 100 | Omlaag ↓
joel12
0
looks like the Usher interim results will be pushed to Q1 2020 .. thats why i see some weakness.. but maybe the CEO will explain or come p with something positive in the presentation today. bummer
Tom3
0
quote:

joel12 schreef op 19 jun 2019 om 17:36:


looks like the Usher interim results will be pushed to Q1 2020 .. thats why i see some weakness.. but maybe the CEO will explain or come p with something positive in the presentation today. bummer

What is your source? Has this been communicated? The JMP securities Life Sciences meeting will be held on june 19th (after closure of the stock market?) +20th. Keep us informed pleased.
RW1963
0
quote:

Tom3 schreef op 18 jun 2019 om 23:51:


[...]

Tja, nu koop je bijna 2,5 ProQR aandelen als je 1 Arrowhead inlevert. Zijn er hier die dat gedaan hebben?


Ik ben toch nieuwsgierig waarom jij dit vraagt?
Zie je meer potentie in ProQR dan in Arrowhead?
Arrowhead draait de laatste tijd toch beter dan ProQR.
Of zit volgens jou Arrowhead nu op het hoogtepunt en ProQR op het dieptepunt?
Heb jij gewisseld?
joel12
2
the presentation is on right now. i simply see the difference of what was communicated previously vs the new presentation.
but now the CEO presents why.. they thought the data will be too thin to had been presented now.

the next data will be the full phase1/2 Sapufrosen in Fall
joel12
1
very powerful presentation from the CEO .. and lots of info including competitive against DNA editing.
Tom3
0
quote:

joel12 schreef op 19 jun 2019 om 18:55:


very powerful presentation from the CEO .. and lots of info including competitive against DNA editing.


Yes I have just heard the final 10 minutes of the presentation. I think the delay was avoidable because the knew what they were doing upfront, so this is a second mistake of Mr de Boer (after the DEB failure). A very costly mistake for De Boer as he is a major shareholder too. We will see what will happen.
ivet
0
betekent niet dat de potentie er minder om is, maar zijn lange processen. Wat wel vervelend is, is dat de boven de effectenmarkten altijd aasgieren circuleren die voordeel willen behalen bij twijfel en onzekerheid. Ik vind het wel jammer dat het er naar uitziet dat het nog een poosje dood geld lijkt te worden....geen actie.

Ik heb toch wel een trauma overgehouden aan UniQure...zat erin op 3,80$...ging ff richting 40$....toen tot onder de 5$ (ik was ondertussen rond 13,50$ uitgestapt omdat feeling weg was)...dobbelde een beetje rond de kaspositie van toen 5$....en nu inmiddels 81$ gezien (anderhalf jaar later!)...het kan verkeren!
Tom3
0
@ ivet, ja het is vandaag weer een dure dag.. De Boer had dit toch van te voren kunnen bedenken. De beursreactie vandaag valt me ergens nog mee ook. Het is een geluk dat 85% van de aandelen bij grote instituten zitten. Wellicht hadden die dit al zien aankomen na de DEB zeperd. Een derde miskleun zou dodelijk kunnen zijn. Kennelijk heeft men sedert dit voorjaar weinig verbetering gezien. Allemaal niet sterk dus.
joel12
2
the DEB never failed .. the product simply doesnt make sense strategically for proqr.

as to the delay .. someone can say it is a sign of confindence that they are kept blinded for a longer period. they simply know they have a good drug.

as to the CEO .. and us shareholders ... PROQR has so many avenues to cut a money , valuable business partnership.. it waits and thats the Dutch way no>? :) patience.
Tom3
0
quote:

joel12 schreef op 19 jun 2019 om 20:47:


the DEB never failed .. the product simply doesnt make sense strategically for proqr.

as to the delay .. someone can say it is a sign of confindence that they are kept blinded for a longer period. they simply know they have a good drug.

as to the CEO .. and us shareholders ... PROQR has so many avenues to cut a money , valuable business partnership.. it waits and thats the Dutch way no>? :) patience.


Hi joel12, If DEB hadn`t been ousted the SP would still have been around $ 16 or higher. It is not clear to me why they haven`t made any hints towards the efficacy of the Usher drug. Have you heard any hint?
ivet
0
quote:

joel12 schreef op 19 jun 2019 om 20:47:


the DEB never failed .. the product simply doesnt make sense strategically for proqr.

as to the delay .. someone can say it is a sign of confindence that they are kept blinded for a longer period. they simply know they have a good drug.

as to the CEO .. and us shareholders ... PROQR has so many avenues to cut a money , valuable business partnership.. it waits and thats the Dutch way no>? :) patience.


agree...other risk perception; the effect on the eye is more predictable but a whole treated body (DEB) is something else!

There is no CEO that can satisfy all shareholders at once!
joel12
1
the company for 1 reason or another keeps the price low for now. the main issue it had was not the DB which is still ongoing and the market for it its not big and does have also a big threat from CRISPr , gene therapy.

the main issue was the safety of the opthamological drug creating cataracts. AND this was given very strong explanation as to why and also competitively in the latest JMP presentation. I feel ever more comfindent about the safety and future of the ophtamological franchise.

many or most small mid cap biotech stocks have gone down in the past mohths, many without any bad news of any kind. as we move towards XBI 90 and beyond they will recover and I hope PRQR as well. the low share price for an intermediate period hope was used by the company to hire good employees and for its big shareholders to consolidate the positions.

Lastly in fall they are faced with a big event! the phase1/2 data.. which runs parallel to phase3. very important for the data to be good. i wonder if they will manage risk by partnering before this event to get money, or raise further capital.
Tom3
0
quote:

joel12 schreef op 20 jun 2019 om 02:44:


the company for 1 reason or another keeps the price low for now. the main issue it had was not the DB which is still ongoing and the market for it its not big and does have also a big threat from CRISPr , gene therapy.

the main issue was the safety of the opthamological drug creating cataracts. AND this was given very strong explanation as to why and also competitively in the latest JMP presentation. I feel ever more comfindent about the safety and future of the ophtamological franchise.

many or most small mid cap biotech stocks have gone down in the past mohths, many without any bad news of any kind. as we move towards XBI 90 and beyond they will recover and I hope PRQR as well. the low share price for an intermediate period hope was used by the company to hire good employees and for its big shareholders to consolidate the positions.

Lastly in fall they are faced with a big event! the phase1/2 data.. which runs parallel to phase3. very important for the data to be good. i wonder if they will manage risk by partnering before this event to get money, or raise further capital.


Thanks for your observations. My issue is that the market now has to believe De Boer regarding the delay: is it a delay only or is it the first step in a complete failure of the Usher trial? I also can`t believe that all the pre- clinical research done and the lca10 trial experience won`t pay off. Still it is very important to manage expectations in a timely fashion. Here De Boer made a glitch. Somehow the market has reacted already as there was no big sell-off yesterday. Volumes were modest. I hope this will continue. Therefore I appreciate your remarks regarding the strong JMP presentation of De Boer, we will need that. Tn my opinion strong Usher data have to trigger a fresh capital increase, as De Boer has plenty of money well into 2021. Investors don`t like to pay for the lca10 data twice.
Guy-vdk
0
Kan het ook in het Nederlands jongens,want niet iedereen kan hier volgen,het is tenslotte een Nederlands forum.
En Proqr gaat weer down,down,down,je kan er blindelings op vertrouwen,terwijl mijn gala aandeeltjes up,up up gaan.Wat een verschil toch.
1.035 Posts, Pagina: « 1 2 3 4 5 6 ... 47 48 49 50 51 52 | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 19-jun-19 22:00
Koers 10,910
Verschil -0,740 (-6,35%)
Hoog 11,720
Laag 10,800
Volume 157.841
Volume gemiddeld 85.338
Volume gisteren 142.305

Brussel real time stocks quotedata by Euronext. Other real time EU stocks, by Cboe Europe Ltd.; US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
# calculated realtime by Commerzbank & '^' by BNP Paribas, streaming powered by VWD Group